Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Clin Breast Cancer. 2016 Aug 1;16(6):487–493. doi: 10.1016/j.clbc.2016.07.013

Table 2.

Outcomes, Per Cohort

4-Year Outcomes No Trastuzumab
(n = 116)
Trastuzumab
(n = 128)
% (95% CI) % (95% CI)
Distant relapse-free survival 97 (92–99) 99 (95–100)
Overall survival 99 (94–100) 99 (95–100)
Ipsilateral invasive breast cancer recurrence   3 (0.3–5.5)   2 (0.2–5.5)
Contralateral invasive breast cancer   1 (1)           0
Second primary invasive cancer (non-breast)   3 (0.13–6.77)   2 (−0.4 to 4.4)

Abbreviation: CI = confidence interval.